Calcivis receives £1.3m investment for tooth decay assessment system
2 May 2014
Oral health company Calcivis has received a UK Biomedical
Catalyst award co-funding a £0.5m development programme and raised a
further £0.8m in equity funding from existing investors Archangel
Informal Investment and the Scottish Investment Bank, the investment
arm of Scottish Enterprise.
The Biomedical Catalyst award will be directed to the further
development of the Calcivis Caries Activity Imaging System, a
medical device and consumable combination designed to transform the
assessment and management of dental caries (tooth decay).
The System is an in-clinic device which combines a sensitive
intraoral camera and application technology to deliver a precise
amount of disclosing solution, containing a photoprotein, onto the
The photoprotein binds calcium ions and emits a blue light signal
proportional to the amount of calcium present. This sensitive
chemiluminescent system produces a demineralisation map of the
tooth. The resulting images provide a focus for discussion with
patients about their caries management programme and the development
of a tailored, rational, evidence-based treatment in line with
dental best practice.
It involves a proprietary bioluminescence approach combined with
a specialised imaging device which allows accurate detection and
visualisation of demineralisation by imaging free calcium ions at
the tooth surface; a caries lesion which is actively demineralising
is more likely to progress and lead to cavitation. The Calcivis
Caries Activity Imaging System was recently granted a CE Mark.
Adam Christie, CEO of Calcivis, said: “We are very pleased to
announce this award from the Biomedical Catalyst and further
investment from Archangels. Together the new funds will allow us to
accelerate the development of the Calcivis System and our progress
towards full commercialisation.
“We believe our system has a role to play in tailored, rational
evidence-based management of tooth decay, one of the most common
diseases in the world and one which can have a significant impact on
Andy Laing of Archangel Informal Investment, said: “Calcivis has
advanced its technology very rapidly to the point where it now has a
CE Mark in readiness for marketing in Europe. Our new investment,
and the Biomedical Catalyst award, will support further clinical
development work and further advances to the technology as the
Company prepares to commercialise the system.”